- Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
[作者:O'Connor, ES; Greenblatt, DY; LoConte, NK; Gangnon, RE; Liou, JI; Heise, CP; Smith, MA,期刊:Journal of clinical oncology, 页码:3381-3388 , 文章类型: Article,,卷期:2011年29-25]
- Purpose Adjuvant chemotherapy is typically considered for patients with stage II colon cancer characterized by poor prognostic features, including obstruction, perforation, emergent admission, T4 stage, resection of fewe...
- Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With EGFR-Activating Mutations
[作者:Yuan, SS; Yu, SL; Chen, HY; Hsu, YC; Su, KY; Chen, HW; Chen, CY; Yu, CJ; Shih, JY; Chang, YL; Cheng, CL; Hsu, CP; Hsia, JY; Lin, CY; Wu, GN; Liu, CH; Wang, CD; Yang, KC; Chen, YW; Lai, YL; Hsu, CC; Lin, TC; Yang, TY; Chen, KC; Hsu, KH; Chen, JJW; Chang, GC; Li, KC; Yang, PC,期刊:Journal of clinical oncology, 页码:3435-3442 , 文章类型: Article,,卷期:2011年29-25]
- Purpose Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been proven more effective for patients with lung adenocarcinoma with EGFR-activating mutation rather than wild type, the fo...
- Biology and Clinical Relevance of the Micropthalmia Family of Transcription Factors in Human Cancer
[作者:Haq, R; Fisher, DE,期刊:Journal of clinical oncology, 页码:3474-3482 , 文章类型: Article,,卷期:2011年29-25]
- Members of the micropthalmia (MiT) family of transcription factors (MITF, TFE3, TFEB, and TFEC) are physiologic regulators of cell growth, differentiation, and survival in several tissue types. Because their dysregulatio...
- Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group
[作者:Sehn, LH; MacDonald, D; Rubin, S; Cantin, G; Rubinger, M; Lemieux, B; Basi, S; Imrie, K; Gascoyne, RD; Sussman, J; Chen, BSE; Djurfeldt, M; Shepherd, L; Couban, S; Crump, M,期刊:Journal of clinical oncology, 页码:3396-3401 , 文章类型: Article,,卷期:2011年29-25]
- Purpose Bortezomib has demonstrated promising activity in patients with follicular lymphoma (FL). This is the first study to evaluate the safety and efficacy of bortezomib added to rituximab, cyclophosphamide, vincristin...
- Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study
[作者:Fowler, N; Kahl, BS; Lee, P; Matous, JV; Cashen, AF; Jacobs, SA; Letzer, J; Amin, B; Williams, ME; Smith, S; Saleh, A; Rosen, P; Shi, HL; Parasuraman, S; Cheson, BD,期刊:Journal of clinical oncology, 页码:3389-3395 , 文章类型: Article,,卷期:2011年29-25]
- Purpose The aims of this multicenter study were to evaluate the response rate, progression-free survival, and toxicity of the combination of bortezomib, bendamustine, and rituximab in patients with follicular lymphoma wh...
- Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?
[作者:Crea, F; Fornaro, L; Masi, G; Falcone, A; Danesi, R; Farrar, W,期刊:Journal of clinical oncology, 页码:3487-3488 , 文章类型: Letter,,卷期:2011年29-25]
-
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
[作者:Perez, EA; Romond, EH; Suman, VJ; Jeong, JH; Davidson, NE; Geyer, CE; Martino, S; Mamounas, EP; Kaufman, PA; Wolmark, N,期刊:Journal of clinical oncology, 页码:3366-3373 , 文章类型: Article,,卷期:2011年29-25]
- Purpose Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large t...
- Coexistence of Differentiated Thyroid Carcinoma With Primary Thyroid Lymphoma in a Background of Hashimoto's Thyroiditis
[作者:Vassilatou, E; Economopoulos, T; Tzanela, M; Rontogianni, D; Karakitsos, P; Magou, C; Hadjidakis, D; Dimitriadis, G,期刊:Journal of clinical oncology, 页码:E709-E712 , 文章类型: Article,,卷期:2011年29-25]
-
- High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
[作者:Moore, RA; Adel, N; Riedel, E; Bhutani, M; Feldman, DR; Tabbara, NE; Soff, G; Parameswaran, R; Hassoun, H,期刊:Journal of clinical oncology, 页码:3466-3473 , 文章类型: Article,,卷期:2011年29-25]
- Purpose This study was designed to determine the incidence of venous and arterial thromboembolic events (TEEs) in patients treated with cisplatin-based chemotherapy and to analyze the prognostic value of patients' baseli...
|